HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.

HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.

Women's sport and women's health enter 2026 not as emergent verticals but as structural components of a global economy under ...

Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography. The study, conducted at Massachusetts General Hospital and ...

Hologic (HOLX) said that achieving the 2026 milestone under its CVR agreement with its sale to Blackstone (BX) and TPG (TPG) will be more challenging after it stopped shipment of a product. In ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Over the past year, we’ve been very active and continue to see deal volume picking up. In terms of a signature moment, this October we announced an agreement for the take-private of Hologic, a global ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making manufacturing inroads in the U.S. by way of an acquisition. Samsung Bio’s U.S.